136 related articles for article (PubMed ID: 38845625)
1. International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea.
Shin EY; Hong YJ; Lim KM; Kim TH; Lee JH
J Pharm Policy Pract; 2024; 17(1):2354299. PubMed ID: 38845625
[TBL] [Abstract][Full Text] [Related]
2. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
Vokinger KN; Kesselheim AS
BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
[TBL] [Abstract][Full Text] [Related]
3. Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017.
Lee SW; Park SH; Song I; Noh Y; Park H; Ha D; Shin JY
Ther Innov Regul Sci; 2020 Mar; 54(2):418-423. PubMed ID: 32072585
[TBL] [Abstract][Full Text] [Related]
4. Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States.
Cho I; Han E
Int J Environ Res Public Health; 2022 Mar; 19(5):. PubMed ID: 35270550
[TBL] [Abstract][Full Text] [Related]
5. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
Nakayama H; Matsumaru N; Tsukamoto K
Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
[TBL] [Abstract][Full Text] [Related]
6. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
7. [Current Status and Issues in Drug Development for Rare Cancers].
Kashitani Y; Takayama H; Hamada N; Go S; Tagami M; Sugihara T
Gan To Kagaku Ryoho; 2023 Nov; 50(11):1150-1154. PubMed ID: 38056864
[TBL] [Abstract][Full Text] [Related]
8. Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020.
Choi H; Lee H; Park B; Kim C; Lee J
Ther Innov Regul Sci; 2023 May; 57(3):552-560. PubMed ID: 36539577
[TBL] [Abstract][Full Text] [Related]
9. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
10. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
[TBL] [Abstract][Full Text] [Related]
11. Delay in Vaccine Access in ASEAN Countries.
Subsittipong N; Choi J; Kim TH; Han E
Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409470
[TBL] [Abstract][Full Text] [Related]
12. Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019).
Lee SH; Yoo SL; Bang JS; Lee JH
Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32357397
[TBL] [Abstract][Full Text] [Related]
13. Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union.
Balkhi B; Almuaither A; Alqahtani S
Saudi Pharm J; 2023 Sep; 31(9):101738. PubMed ID: 37638213
[TBL] [Abstract][Full Text] [Related]
14. Analysis and comparative evaluation of expedited programs for gene therapy products: insights from the United States, the European Union, Japan, and South Korea.
Jeong H; Purja S; Kim E
Gene Ther; 2024 May; 31(5-6):242-254. PubMed ID: 38200263
[TBL] [Abstract][Full Text] [Related]
15. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.
Murakami M; Narukawa M
Drug Discov Today; 2016 Apr; 21(4):544-9. PubMed ID: 26945941
[TBL] [Abstract][Full Text] [Related]
16. Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications.
Kwon HY; Kim H; Godman B
Front Pharmacol; 2018; 9():938. PubMed ID: 30233363
[No Abstract] [Full Text] [Related]
17. Analysis of Pediatric Drug Approval Lag in Japan.
Ueyama E; Kaneko M; Narukawa M
Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
[TBL] [Abstract][Full Text] [Related]
18. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
Tsuji K; Tsutani K
J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
[TBL] [Abstract][Full Text] [Related]
19. Effect of the copayment reduction system on accessibility to orphan drugs in South Korea.
Hwang SE; Kim M; Hong Y; Lee D; Kim T; Park J; Bae J; Lee JH
Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):519-525. PubMed ID: 36922505
[TBL] [Abstract][Full Text] [Related]
20. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
Blankart CR; Stargardt T; Schreyögg J
Pharmacoeconomics; 2011 Jan; 29(1):63-82. PubMed ID: 21073206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
